Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics

Berenguer, Juan; Rivero, Antonio; Jarrín, Inmaculada; Núñez, María; Vivancos, María Jesús; Crespo, Manel; Téllez, María J.; Domingo, Peré; Iribarren, José Antonio; Artero, Arturo; Márquez, Manuel; Santos, Ignacio; Moreno, J. Marta; Montero, Marta; González-García, Juan

doi:10.1093/ofid/ofw059

Cited by 34 publications

(42 citation statements)

References 18 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Coinfections with other viruses that, such as HIV and HBV, share the same transmission routes showed that patterns and prevalences are similar, except for genotype 1, for which subtype 1a predominates over 1b in HIV‐coinfected patients, this being the opposite trend to those coinfected with HBV. The genotypes pattern in coinfection by HIV, as expected, was similar to that in PWID and confirms that this group was mainly predominant in HIV‐coinfected patients …”

Section: Discussionsupporting

confidence: 83%

“…Mixed HCV genotypes are not included in the data for GEHEP 005, as they were not reported in the study by Echevarria et al ND those coinfected with HBV. The genotypes pattern in coinfection by HIV, as expected, was similar to that in PWID and confirms that this group was mainly predominant in HIV-coinfected patients 33. This study examined the geographical distribution of the HCV genotypes in Spain globally and also in the different geographical regions and SACs considered.…”

supporting

confidence: 79%

“…Despite the epidemiological characteristics of GEHEP 005 and having included a large population of patients with chronic hepatitis C from many hospitals all over Spain to ensure the representativeness and external validity of the present study, we believe that this study has some limitations. Apart from the limitations of retrospective studies, we also found some related to the methods mainly employed herein for HCV genotyping; this limitation refers to the correct viral subtype determination of genotype 1, especially when comparing commercial to reference methods based on sequencing and phylogenetic analyses of the NS5B region of HCV . In this regard, the inclusion of HCV genotyping by sequencing‐based technologies of different viral genome regions may notably improve viral subtype knowledge, which is still important for choosing the most appropriate treatment regimen and for determining resistance‐associated substitutions (RAS).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000‐2015 period (the GEHEP 005 study)

Aguilera

Navarro

Rodríguez‐Frías

et al. 2017

Journal of Viral Hepatitis

View full text Add to dashboard Cite

We report the largest study on the prevalence and distribution of HCV genotypes in Spain (2000-2015), and we relate them with clinical, epidemiological and virological factors. Patients from 29 hospitals in 10 autonomous communities (Andalusia, Aragon, Castilla-Leon, Catalonia, Galicia, Canary Islands, Madrid Community, Valencian Community, Murcia Region and Basque Country) have been studied. Annual distribution of HCV genotypes and subtypes, as well as gender, age, transmission route, HIV and/or HBV coinfection, and treatment details were recorded. We included 48595 chronically HCV-infected patients with the following characteristics: median age 51 years (IQR, 44-58), 67.9% male, 19.1% HIV-coinfected, 23.5% HBV-coinfected. Parenteral transmission route was the most frequent (58.7%). Genotype distribution was 66.9% GT1 (24.9% subtype 1a and 37.9% subtype 1b), 2.8% GT2, 17.3% GT3, 11.4% GT4 and 0.1% GT5 and 0.02% GT6. LiPA was the most widely HCV genotyping test used (52.4%). HCV subtype 1a and genotypes 3 and 4 were closely associated with male gender, parenteral route of infection and HIV and HBV coinfection; in contrast, subtype 1b and genotype 2 were associated with female gender, nonparenteral route and mono-infection. Age was related to genotype distribution, and different patterns of distribution and biodiversity index were observed between different geographical areas. Finally, we describe how treatment and changes in transmission routes may have affected HCV genotype prevalence and distribution patterns. We present the most recent data on molecular epidemiology of hepatitis C virus in Spain. This study confirms that genotype distributions vary with age, sex, HIV and HBV coinfection and within geographical areas and epidemiological groups.

show abstract

Section: Discussionsupporting

confidence: 83%

supporting

confidence: 79%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000‐2015 period (the GEHEP 005 study)

Aguilera

Navarro

Rodríguez‐Frías

et al. 2017

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…We also used reports from two Spanish national cohorts: the “Grupo de Estudio de Sida” (GeSIDA) [10] and the “Asociación Médica VACH de Estudios Multicentricos (AMVACH)” [22] (Table B in S1 File). …”

Section: Methodsmentioning

confidence: 99%

Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era

et al. 2017

Self Cite

View full text Add to dashboard Cite

The incidence of stroke in human immunodeficiency virus (HIV)–infected individuals has been well analyzed in recent epidemiological studies. However, little is known about the specific contribution of hepatitis C virus (HCV) infection to stroke among HIV-infected individuals. The aims of this study were to analyze trends in the incidence rates of stroke in HIV-infected individuals during the combination antiretroviral (cART) era in Spain and to categorize them by the presence or absence of HCV coinfection. We analyzed hospital discharges with a diagnosis of stroke in Spain according to ICD-9-CM during 1997–2013. The study period was divided into four calendar periods (1997–1999, 2000–2003, 2004–2007, and 2008–2013). Patients were classified according to HCV serology. The number of HIV-infected patients was estimated based on data from the National Centre of Epidemiology. We calculated incidence rates (events per 10,000 patient-years) and in-hospital case fatality rates (CFR). The incidence of hemorrhagic stroke (HS) decreased in HIV-monoinfected patients (15.8 [1997–1999] to 6.5 [2008–2013]; P<0.001) and increased in HIV/HCV-coinfected patients (1.3 [1997–1999] to 5.5 [2008–2013]; P<0.001). The incidence of ischemic stroke (IS) decreased in HIV-monoinfected patients (27.4 [1997–1999] to 21.7 [2008–2013]; P = 0.005) and increased in HIV/HCV-coinfected patients (1.8 [1997–1999] to 11.9 [2008–2013]; P<0.001). The CFR was 3.3 times higher for HS than for IS for the whole study period. The CFR of HS in HIV-monoinfected patients decreased significantly (47.4% [1997–1999] to 30.6% [2008–2013]; P = 0.010) but did not change significantly among HIV/HCV-coinfected patients (41.4% [1997–1999] to 44.7% [2008–2013]; P = 0.784). The CFR of IS in the whole HIV-infected population decreased significantly (14.6% [1997–1999] to 10.9% [2008–2013]; P = 0.034), although no significant differences were found when each group was analyzed separately. In conclusion, after the introduction of cART, HS and IS rates decreased in HIV-monoinfected individuals, but increased steadily in HIV/HCV-coinfected individuals.

show abstract

“…Analysis of non-AIDS events in a Spanish cohort of 320 HIV controllers implicated HCV co-infection as the predominant factor contributing to hepatic and extra-hepatic non-AIDS defining clinical events [32]. Similarly, HCV infection significantly contributed to excess mortality observed in a large Spanish HIV-infected cohort (10,340 persons) between 2004–14 [33], and 22.1% of HIV-infected persons in Spain were estimated to have HCV co-infection in 2015 [34]. …”

Section: Prevalence and Morbidity Associated With Co-infectionmentioning

confidence: 99%

Update in HIV–hepatitis C virus coinfection in the direct acting antiviral era

Meissner

2017

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

Purpose of Review Availability of direct acting antivirals (DAAs) that demonstrate remarkable clinical efficacy and safety has revolutionized the ability to treat chronic infection with hepatitis C virus (HCV). An equal measure of clinical success has now been achieved in persons co-infected with HCV and the human immunodeficiency virus (HIV), a historically harder to cure cohort with interferon-based therapy. Global goals include identifying all HIV/HCV-infected persons, gaining access to DAA-therapy, preventing de novo and re-infection, and managing the sequelae of chronic infection. This review will discuss advances in the field of HIV/HCV co-infection reported during the last 18 months, and will suggest areas for future investigation. Recent Findings An expanding body of literature has enhanced our understanding of the clinical and epidemiologic issues surrounding HIV/HCV co-infection. DAA therapy for HCV is highly efficacious in HIV/HCV co-infected persons if drug-drug interactions are appropriately considered. Summary Eradicating HCV infection in persons with HIV co-infection can be achieved safely and effectively with available DAAs. Economic and social approaches to enable access and delivery of curative HCV therapy to HIV-infected persons require continued research and resource allocation.

show abstract

Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics

Abstract: The prevalence of HCV coinfection in HIV-infected individuals in Spain has decreased significantly in the last decade. Patients with active HCV infection mainly have genotypes 1a and 4, and a high percentage have liver cirrhosis.

Cited by 34 publications

References 18 publications

Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000‐2015 period (the GEHEP 005 study)

Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000‐2015 period (the GEHEP 005 study)

Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era

Update in HIV–hepatitis C virus coinfection in the direct acting antiviral era

Contact Info

Product

Resources

About